统一服务热线:400-888-0207 在线咨询 | 微信联系
首页 > 产品 > 产品类型 > 抗体 > 一抗
Human LRP1 Cluster III, chiMAX Fc Fusion Protein
货号:HLRP-C3-FC | 规格:0.05 mg | 价格:¥0.00 | 品牌:Molecular Innovations
Human LRP1 Cluster III, chiMAX Fc Fusion Protein是由北京中昊新生科技有限公司提供,Molecular Innovations专注于凝血和溶栓试剂,包括PAI-865、tPA、尿激酶、凝血因子、玻连蛋白、纤维蛋白原、纤连蛋白、肾素原/肾素、前激肽释放酶、激肽释放酶、白蛋白、纤溶酶原、纤溶酶、抗纤溶酶、凝血酶、抗凝血酶、补体成分和免疫球蛋白。
Low density lipoprotein receptor-related protein 1 (LRP1, LRP-1), also known as alpha-2-macroglobulin receptor (A2MR), cluster of differentiation 91 (CD91), and apolipoprotein E receptor (APOER), is a plasma membrane receptor protein that is expressed as a non-covalently associated 515 kDa alpha chain and 85 kDa beta chain. LRP-1 binds a wide variety of targets, is involved in a number of cell signaling and clearance events, and is clinically implicated in cardiovascular disease, cancer, and Alzheimer's disease. Human LRP1 Cluster III (Ser2522-Ile2941) is located on the alpha chain and contains 10 cysteine rich ligand binding domains known as LDL receptor type A repeats (LDLa). Expressed recombinantly as a fusion protein with a C-terminal DIEGRMD linking sequence and Fc tag, purified by chromatography, sterile filtered and lyophilized. >95percent pure by SDS-PAGE and binds with high affinity to receptor associated protein (RAP) with a kD of <3nM as determined by Biacore surface plasmon resonance analysis. Add deionized water to original volume, aliquot and freeze unused portion.
This chiMAX Fc Fusion Protein is glycosylated and expressed as a chimera with the Fc region of mouse immunoglobulin (heavy chain hinge, CH2 and CH3). Fc fusion proteins are typically more stable and resistant to degradation and clearance than native cytokines. Fc fusion proteins appear as a dimer in SDS-PAGE under non-reducing conditions.
References
Dudley K. Strickland, Dianaly T. Au, Patricia Cunfer, and Selen C. Muratoglu. Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity. Arteriosclerosis, Thrombosis, and Vascular Biology 2014, 34:487–498.
相关产品
相关资料